- Just – Evotec Biologics is transforming biomanufacturing with a fully integrated, continuous manufacturing platform from discovery to cGMP production
- Advanced technologies reduce costs, improve speed to market, and maintain top-tier quality from the clinical to the commercial stage
- Our modular state-of-the art J.POD facilities are fully flexible in response to demand fluctuations and can be deployed globally to support expanded access to biotherapeutics
- We are partnering with leading biotech, pharma, biosimilar players, and governments to drive these advancements as the fastest growing CTDMO
Kevin Ingham
Vice President of Manufacturing Operations
Just – Evotec Biologics
Kevin has over 20 years of biologics manufacturing experience for both innovators and CDMOs in all phases of molecule lifecycles. He currently leads Just’s innovative J.POD continuous manufacturing site in Redmond, WA.
—
Just – Evotec Biologics
Just – Evotec Biologics, wholly owned by Evotec SE, is a CDMO offering development and manufacturing services for antibody, next-generation biologics, and biosimilar products. We collaborate with partners starting from antibody discovery through process development and manufacturing with sites in US and Europe. We designed our technologies to reduce cost of goods and help expand global access to affordable high-quality biotherapeutics. Our team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics.
